Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities (Tables)

v3.24.3
Accrued Expenses and Other Current Liabilities (Tables)
9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

 

 

September 30, 2024

 

 

December 31, 2023

 

External research and preclinical development

 

$

9,984

 

 

$

8,001

 

Employee compensation and benefits

 

 

4,788

 

 

 

6,993

 

Professional fees

 

 

707

 

 

 

1,015

 

Facilities and other

 

 

683

 

 

 

137

 

Accrued expenses and other current liabilities

 

$

16,162

 

 

$

16,146